Skip to the reading
The BPC
question kit

A guide to checking care

Your notes
Chapter index

Care concerns

Leave room for what is not known.

Ask the clinician to name the gaps as clearly as the hoped-for benefit. Bring questions about your own health and medicines.

Small studies cannot settle harm.

The Food and Drug Administration (FDA) found too little information from people to describe BPC-157’s safety well as of September 28, 2026.

The FDA noted that studies were short, small and unclear about how they watched for harm.

Read the basisFDA human harm assessment, PDF

Medicine reviews in the U.S. are handled by the FDA. Ask what the uncertainty means for the choice being discussed.

There is no reviewed label to fill the gaps.

BPC-157 had no FDA-approved label—official instructions for its use—as of September 28, 2026.

So there is no FDA-reviewed information there on pregnancy, who must avoid it, or what might happen when it is taken with other medicines.

The human studies reviewed by the FDA did not study pregnancy.

Read the basisFDA review and study populations, PDF

A purity figure is not the whole test.

In its BPC-157 review, the FDA found test certificates that reported purity without enough information about unwanted substances.

For injections, the FDA also calls for tests for germs, poisons those germs can leave behind, and bits of unwanted material.

Read the basisFDA review of product quality, PDF

A test certificate reports checks on a batch, meaning a group made together. Ask the clinician to explain what those checks can and cannot show.

Severe symptoms need urgent help.

The U.S. National Library of Medicine provides MedlinePlus, a health resource that identifies a severe allergic reaction as an emergency.

Call 911 or go immediately to your closest emergency room for severe allergy symptoms such as breathing difficulty or swelling in your tongue or face.

Read the basisMedlinePlus: severe allergic reactions

A patient can report a problem.

The FDA’s free MedWatch service lets patients report a medicine problem they suspect.

Read the basisFDA MedWatch reporting information

Keep the label and the written plan available when discussing a problem with a clinician.